logo

For the Inventor, By the Inventor

Thane, India

Srikanth Annappa Pai

This inventor holds 7 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Bharat Serums and Vaccines Limited, Other. Active years: 2003-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srikanth Annappa Pai. Retrieved from https://idiyas.com/inventor/srikanth-annappa-pai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 71.4

 

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 13(Granted Patents)


Location History:

  • Maharashtra, IN (2006)
  • Mumbai, IN (2014)
  • Thane, IN (2003 - 2015)

Company Filing History:

goldMedal6 out of 11 
 
Bharat Serums and Vaccines Limited
 patents
silverMedal1 out of 834,513 
Other
 patents

Years Active: 2003-2015

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 9005655 - Non-pegylated long-circulating liposomes (2015-04-14),
2. 8980310 - Non-pegylated long-circulating liposomes (2015-03-17),
3. 8759404 - Intravenous propofol emulsion compositions having preservative efficacy (2014-06-24),
4. 7199111 - Aqueous ifosfamide compositions for parenteral administration and a process for their preparations (2007-04-03),
5. 7138387 - Clear aqueous composition comprising propofol and hydroxypropyl-beta-cyclodextrin (2006-11-21),
6. 7053061 - Amphotercin B structured emulsion (2006-05-30),
7. 6572884 - Parenteral Cisplatin emulsion (2003-06-03),

Title: Srikanth Annappa Pai: Innovator in Liposomal Drug Delivery

Introduction

Srikanth Annappa Pai is a notable inventor based in Thane, India. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of innovative drug delivery systems. With a total of 7 patents to his name, his work has the potential to impact cancer treatment significantly.

Latest Patents

One of his latest patents involves the creation of non-pegylated long-circulating liposomes. This invention provides a long-circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration. The process for its preparation is also detailed in the patent. The circulation time in Swiss albino mice is at least 25 times longer than that of conventional non-liposomal formulations. These non-pegylated liposomes are stable, exhibit low toxicity, and have been found to be efficacious in various tumor models.

Career Highlights

Throughout his career, Srikanth has worked with prominent organizations, including Bharat Serums and Vaccines Limited. His expertise in pharmaceutical formulations has been instrumental in advancing drug delivery technologies.

Collaborations

Some of his notable coworkers include Sangeeta Hanurmesh Rivankar and Gautam Vinod Daftary. Their collaborative efforts have contributed to the success of various projects in the pharmaceutical sector.

Conclusion

Srikanth Annappa Pai's innovative work in liposomal drug delivery systems showcases his commitment to improving cancer treatment options. His patents reflect a deep understanding of pharmaceutical technology and a dedication to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…